Skip to content
logo with text
  • What we do
    • Scouting and Out-Licensing
    • Consulting to BD&L
    • Training
  • Current Projects
    • Topical Candidate for Eczema and Related Conditions
    • Custom Nanocomplex Formulation Opportunities
  • About Us
  • Contact
Menu
  • What we do
    • Scouting and Out-Licensing
    • Consulting to BD&L
    • Training
  • Current Projects
    • Topical Candidate for Eczema and Related Conditions
    • Custom Nanocomplex Formulation Opportunities
  • About Us
  • Contact

Covance does it again…this time in Europe

  • Post author:Carlos
  • Post published:September 30, 2010
  • Post category:CRO/Europe/Pharmaceutical

Today we hear the news that Covance has done it again. Today they acquired two European R&D sites from Sanofi for $25 million. In addition, Sanofi agreed to purchase R&D…

Continue ReadingCovance does it again…this time in Europe

Recent Posts

  • Year in Review Video – 2024 Edition
  • Pre-BIO-Europe 24 Primer Sunday November 3
  • How much does it cost?
  • Does Management Matter?
  • Benefits & pitfalls of performing a valuation during out-licensing

Archives

  • December 2024
  • October 2024
  • September 2024
  • April 2024
  • May 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • June 2022
  • March 2022
  • June 2021
  • February 2021
  • December 2020
  • September 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • May 2014
  • April 2014
  • February 2014
  • January 2014
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010

Categories

  • Artificial Intelligence
  • Biosimilars
  • Biotech
  • Business Development/Licensing
  • China
  • Conferences
  • COVID-19
  • CRO
  • Diagnostics
  • Digital Health
  • Digital Medicine
  • Downsizing
  • Drug Delivery
  • Drug Development
  • Drug Discovery
  • Due Diligence
  • Emerging Markets
  • Entrepreneurship
  • Europe
  • Financing
  • Generics
  • Government
  • India
  • Marketing
  • Mergers & Acquisitions
  • Offshoring
  • Outsourcing
  • Pharmaceutical
  • Planning
  • Pricing
  • Reimbursement
  • Social Media
  • Tech Transfer
  • Uncategorized
  • Venture Capital

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Get in touch

To contact us, please email us at mail: info@lacertabio.com to schedule your free consultation, or call tele:+1 (845) 293-3343.

Free sketch of your website? Try Weblify.se

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoPrivacy policy